CASE REPORT article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1556851
Case Report: Split liver transplantation for graft liver failure due to antibody-mediated rejection after immune checkpoint inhibitor therapy
Provisionally accepted
- Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: To explore the clinical experience of split liver transplantation (SLT) as a salvage treatment for acute graft failure (AGF) caused by immune checkpoint inhibitors (ICIs).The clinical data of one hepatocellular carcinoma (HCC) patient who underwent two liver transplants were retrospectively reviewed.The patient received multiple PD-1/PD-L1 inhibitor treatments, with the last one administered 16 days prior to the first transplant. On postoperative day 7, there was a rapid increase in transaminases, indicating acute rejection, which was treated with additional Rabbit anti-human thymocyte immunoglobulin(ATG). On day 14, the patient presented with fatigue, shortness of breath, and abdominal distension. An ultrasound revealed reversed portal vein flow and significant liver enlargement. Given the patient's deteriorating condition, a rescue second liver transplant (complete right lobe split liver transplantation with middle hepatic vein bipartition/reconstruction) was performed on day 16. The anti-rejection regimen included ATG, Baliximab, Rituximab, glucocorticoids, and intravenous immunoglobulin (IVIG). Postoperative pathology indicated acute liver failure due to humoral rejection. The patient has since been followed for over 12 months, with stable liver function and no signs of rejection or tumor recurrence.Conclusions: This case highlights the need for cautious use of ICIs before liver transplantation and supports SLT as an effective option in cases of AGF.
Keywords: Hepatocellular carcinoma(HCC), Immune Checkpoint Inhibitors(ICIs), Acute graft failure(AGF), Antibody-mediated rejection(AMR), Split liver transplantation(SLT)
Received: 07 Jan 2025; Accepted: 11 Aug 2025.
Copyright: © 2025 Tang, Fu, Yang, Yao, Zeng, Feng, Yi and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Shuhong Yi, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.